Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPI comparison in high-risk acute coronary syndrome patients undergoing PCI
ACTRN12607000328471Phase 4Completed
- Sponsor
- A/Professor Craig Juergens
- Start
- Sep 2007
- Modality
- Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in acute coronary syndrome (ACS) comparing Tirofiban, Eptifibatide and Abciximab (3 arms). Primary endpoint: Primary: Degree of glycoprotein IIb/IIIa platelet receptor inhibition during PCI. Started Sep 2007; status: completed.
02
Drugs
tirofibaneptifibatideabciximab
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ACTRN12607000328471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000328471.